drugset / Trial / NCT05304364

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

NCT05304364

Phase 1 Completed 10 enrolled Delpor, Inc.
NaSequentialOpen-labelTreatment

Summary

This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®

Timeline

Start
2022-03-22
Primary completion
2022-10-21
Completion
2022-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 50 mg Oral